title: Omalizumab use during pregnancy for CIU: a tertiary care experience.
abstract: The treatment of antihistamine and steroid resistant Chronic Idiopathic Urticaria (CIU) during pregnancy poses a challenge due to teratogenicity of immunosuppressants. Omalizumab is a recently FDA approved therapy for CIU and is classified as pregnancy category B. We present an initial series of subjects treated at a tertiary care center for antihistamine and steroid resistant CIU with omalizumab who became pregnant during therapy.
authors.affiliation: Medicine Institute, Cleveland Clinic, OH, USA.
authors.forename: L
authors.initials: L
authors.lastname: Cuervo-Pardo
authors.affiliation: Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, OH, USA.
authors.forename: M
authors.initials: M
authors.lastname: Barcena-Blanch
authors.affiliation: Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic. 9500 Euclid Ave, A90, Cleveland, OH 44195, USA Phone: +1 216 986 4000 Fax: +1 216 445 2104 E-mail: radojic@ccf.org.
authors.forename: C
authors.initials: C
authors.lastname: Radojicic
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009820:Ohio; D000069444:Omalizumab / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000188:drug therapy*; D012074:Remission Induction; D018570:Risk Assessment; D062606:Tertiary Care Centers; D016896:Treatment Outcome; D014581:Urticaria / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D007166:Immunosuppressive Agents; D000069444:Omalizumab
keywords: Omalizumab; pregnancy; urticaria